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Summary.-The disappearance rate (k) of i.v. glucose was measured in cachectic and
non-cachectic cancer patients and tumour-free controls. The respective k values were
found to be 106+027 (mean+s.d.), 164±034 and 163±023. Ofthe other parameters
measured, only plasma albumin level was found to vary significantly amongst the 3
categories, the mean level being the lowest in cachectic cancer patients. The means of
total plasma protein, fasting blood glucose and plasma liver enzyme concentrations
were similar in the 3 groups. Glucagon, a potent insulin secretogogue, failed to aug-
ment the fasting insulin level in cachectic but did so in non-cachectic cancer patients.
Taken together, the findings suggest that the reduced glucose tolerance in patients
with neoplasia is due to impairment of insulin release exhibited predominantly by
ill-nourished advanced cancer patients having a moderate to severe degree of
hypoalbuminemia.
GLUCOSE intolerance has long been
recognized as a manifestation of cancer
(Edwards, 1919). It has been shown that
the impaired glucose tolerance in neoplasia
is independent of age, sex and ethnic
origin, and it occurs irrespective of the
type of tumour (Glicksman and Rawson,
1956). Tumour-bearingpatients, ingeneral,
have fasting blood glucose and immuno-
reactive insulin concentrations similar to
those observed in tumour-free controls
(Holroyde et al., 1975) even though they
have a markedly subnormal disappearance
rate ofintravenously given glucose (Marks
and Bishop, 1956; 1957). The origin of
cancer-associated glucose intolerance re-
mains, however, obscure (Glicksman and
Rawson, 1956).
Recent studies on malnourished children
(Milner, 1971), adults (Smith et al., 1975)
and animals (Heard, 1966; Weinkove et al.,
1976) conclusively demonstrate that mal-
nutrition can lead to glucose intolerance.
In particular the work on malnourished
animals (Weinkove et al., 1976) has
implicated protein deficiency as an
important precursor of impaired carbo-
hydrate metabolism. For instance, wean-
ling rats fed a protein-deficient diet and
challenged with i.v. glucose, showed a
markedly reduced rate ofdisappearance of
glucose from the blood, compared with
normally fed animals. The mean fasting
blood-glucose level of the protein-starved
rats was found to be similar to that for the
controls. This situation is very like that
seen in patients with cancer, andmakesone
think that glucose intolerance in such
patients could be due to a form of protein
deficiency. To examine this possibility
we have studied both well-nourished and
ill-nourished cancer patients with respect
to their glucose tolerance and protein
status.
METHODS AND MATERIALS
Patients.-Of 40 patients studied, 30 had
metastatic cancer; 15 being classified as non-
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cachectic and the rest as cachectic. A patient
was defined as cachectic if he displayed
anorexia, progressive weight loss and wasting.
The type and extent ofthe malignant disease
was diagnosed in all but 2 cases by laparo-
tomy. In these 2 cases, one with carcinoma of
the tongue had clinically detectable regional
lymph nodes, and one had carcinoma of the
bronchus with cerebellar metastases dis-
covered at subsequent autopsy. Any patient
with diabetes mellitus or other pancreatic
pathology, recent major haemnorrhage, sepsis
or intestinal obstruction was excluded from
the study. The remaining 10 patients were
well-nourished routine hospital cases who
were included as controls. Every patient had
agreed to cooperate in the study, the protocol
of which had been initially approved by the
local ethical committee.
Intravenous glucose tolerance test.-Thirty
patients (10 cachectic and 10 non-cachectic
cancer patients, and 10 control patients) were
starved overnight in preparation for i.v.
glucose tolerance test which was performed as
follows. A fasting venous blood sample was
taken for the estimation of glucose and liver-
function. Fifty ml of 50% dextrose solution
was then injected over a 2 min period into a
relatively large vein. Further blood samples
for glucose estimation were taken at 10, 20
and 30 min intervals. Linear regression
analysis was performed on the logarithmic
values obtained forthe blood-glucose samples.
From the slope ofthe regression line obtained,
the k value was calculated in each case and
expressed as percentage glucose disappear-
ance per minute.
Glucagon-mediated insulin release.-Gluca-
gon, a hormone which is known to induce
release of pre-formed insulin (Grodsky et al.,
1967) was usedto studythe secretory capacity
for pancreatic insulin of5 cachectic and 5 non-
cachectic cancer patients not included in the
glucose-tolerance trial. From each patient a
fasting venous-blood sample was initially
taken for estimation ofinsulin using a specific
radio-immunoassay (Albano et at., 1972). The
patient was then subjected to an i.v. injection
of glucagon (Eli Lilley & Co.; 0-05 mg/kg
body weight) and further blood samples were
taken forinsulin analysis at 15, 30 and 45 min.
The cumulative insulin response was calcu-
lated by adding together the differences
between the fasting insulin level and the level
achieved at each sampling time.
RESULTS
The detailed characteristics and results
of non-cachectic and cachectic cancer
TABLE I.-Non-cachectic cancer patients
Sex &
age
Case (years)
1 M
48
2 M
55
3 M
72
4 M
58
5 M
74
6 M
69
7 M
54
8 M
56
9 M
61
10 F
70
Extent of
Primary site metastases
Rectum Liver
Rectum
Tongue
Lymphosarcoma
Bladder
Colon
Stomach
Colon
Stomach
Ovary
RLN*
RLN
RLN
Spine
RLN
RLN
RLN
Liver
Fasting
glucose
(mM)
3 -8
k
(0%/min)
1-40
4-6 1-38
4-1 1-43
4-5 2-21
5.3 1-68
4-4 1-82
Albumin
(g/l)
35
Total
protein
(g/l)
66
Liver
enzymes
Raised
36 63 Normal
38 72 Normal
41 68 Normal
43 74 Normal
43 70 Normal
5 -0 1 -73 43 62 Raised
5-0 1-29
3 - 7 2-12 27 52 Normal
Peritoneum 5 - 3 1-29
* Regional lymph nodes.
41 67 Normal
31 64 Normal
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TABLE II.-Cachectic cancer patients
Primary site
Colon
Colon
Lung
Stomach
Stomach
Ovary
Oesophagus
Rectum
Rectum
Ovary
Hydro4
Electiv
Benign
Duodei
Benign
Periph
Gall st(
Haemo
Inguint
Gastric
Extent of
metastases
Liver;
spine
Liver
Brain
Peritoneum
RLN
Peritoneum
RLN
RLN
Liver
Peritoneum
Fasting
glucose
(mM)
4-9
4.3
4-2
5-3
5*0
6-1
4.4
5-5
6 2
3 7
k
(%/min)
1 -06
0.99
0-71
1-15
0-87
1-17
1*15
0-92
1-68
0-86
TABLE III.-Tumour-free control patients
Fasting
glucose k All
Diagnosis (mM) (%/min)
cele 4-8 1-77
re appendicectomy 4-3 1b29
i prostatic hypertrophy 4-4 1-24
nal ulcer 4- 7 1-75
prostatic hypertrophy 5.1 1.70
eral vascular disease 3 8 1 -79
ones 4.2 1-56
rrhoids 4-2 1 56
al hernia 4.4 1-59
ulcer 3 9 1-63
patients are shown in Tables I and II
respectively. The corresponding features of
control patients are in Table III. Table IV
summarizes the means and standard devi-
ations of the various parameters in the 3
patient categories. It can be seen that the
mean k value of cachectic patients differs
20
Total
Albumin protein
(g/l) (g/l)
Liver
enzymes
29 73 Normal
31
35
30
34
30
36
39
30
39
bumin
(g/l)
35
40
39
41
43
45
43
43
41
45
62
76
60
59
62
61
70
58
62
Total
protein
(g/l)
66
63
64
65
74
76
69
69
66
69
Raised
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Liver
enzymes
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
significantly (t==424; P<0001) from that
for non-cachectic cancer patients and the
controls, which were virtually identical.
The mean serum albumin levels for the
last 2 categories of patients are seen to be
appreciably higher than those for the
cachectic cancer patients. For the com-
Case
1
2
3
4
5
6
7
8
9
10
Case
1
2
3
4
5
6
7
8
9
10
Sex &
Age
(years)
M
44
M
75
M
73
F
56
F
84
F
72
M
67
M
62
M
82
F
63
Sex &
Age
(years)
M
64
F
25
M
71
F
33
M
67
M
62
F
48
M
60
M
57
F
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TABLE IV.-Summary of datafor cachectic and non-cachectic cancer patients and
tumour-free controls
Total protein
(g/l)
Mean±s.d.
64+6
66±6
68±4
Fasting glucose Number ofcases
(mM) with raised liver
Mean±s.d. enzyme levels
5-0±0-8 1
4-6±0-6
4 5±0 3
2
0
TABLE V.-Insulin response to glucagon stimulation
Plasma Insulin
(mU/l)
45
min
10
3
4
11
11
24
18
40
33
31
Cumulative
insulin
response
over 45 min
0
12
8
14
24
69
49
67
74
127
parison cachecticpatients vs. non-cachectic
patients, t 2-13 (P<0.05) and for
cachectic vs. tumour-free controls, t=5-42
(P<0.001). On the other hand, there seems
to be no clear difference in mean total
protein or fasting glucose levels between
the 3 categories. Only 1/10 cachectic and
2/10 non-cachectic patients had raised
levels of liver enzymes.
Table V compares the insulin response to
glucagon challenge in cachectic and non-
cachectic cancer patients. It can be seen
that whereas glucagon consistently aug-
mented the fasting insulin levels of non-
cachectic cancer patients, it had only a
marginal effect in cachectic tumour
patients.
DISCUSSION
The results demonstrate a definite
association between impairedglucosetQler-
ance and cachexia in neoplasia. Cachexia
is, in turn, seen to be associated with
hypoalbuminemia, a feature which has
been observed by several previous workers
(Ariel, 1949; Winzler, 1953; Peden et al.,
1957).
Alteration in the functional capacity of
the liver (the major site of albumin
synthesis) (Madden and Whipple, 1940)
does not seem to be responsible for the
low levels of circulating albumin observed
in neoplastic cachexia (Winzler, 1953). Our
data are consistent with this thesis.
Hence, in the absence of any gastro-
intestinal disturbance, chronic haemorr-
hage, or sepsis, hypoalbuminemia, in
advanced cancer patients, is likely to arise
from either increased protein breakdown,
excessive utilization of protein by the
tumour, reduced protein intake, or a
combination of these. Several previous
investigations have failed to demonstrate
a protein-losing catabolic state in malig-
nant cachexia (Waterhouse et al., 1951;
Fenninger and Mider, 1954; Holroyde et
al., 1975).
On the other hand, protein loss (in
terms of nitrogen) experienced during
tumour growth seems to follow a pattern
Patient
(No.)
Cachectic
(10)
Non-cachectic
(10)
Control
(10)
k
(%/min)
Mean±s.d.
1-06+0-27
1-64±0 34
1 63±0-23
Albumin
(g/l)
Mean±s.d.
33±4
38+6
42±3
Category
Cachectic
Non-cachectic
Patient
1
2
3
4
5
6
7
8
9
10
0
min
10
3
4
8
4
5
8
16
10
6
15
min
10
3
8
13
17
35
36
34
38
64
30
min
10
15
8
14
8
25
19
41
33
50
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very similar to that observed during
dietarystarvation. Forexample,thetissues
and organs which lose nitrogen during
starvation are the ones that lose nitrogen
during tumour growth (Sherman et al.,
1950). Evidently, protein deprivation in
advanced cancer seems to arise not only
from anorexia, the major cause ofcachexia
(Theologides, 1972) but also from
monopolization of the host's protein
metabolic pool by the tumour tissue (Mider
et al., 1948). It follows that cancer
patients suffer from protein malnutrition
derivedfrom both alowdietaryintake and
preferential utilization of protein meta-
bolites by the tumour. The resulting
protein-deficient state is hence analogous
to that experimentally induced in normal
weanling rats by Weinkove et al. (1976),
since not only were these rats on a low
protein diet, but they were in a phase of
rapid growth, a state which in itself,
utilizes a high level of protein.
The reason for impaired carbohydrate
metabolism in the rat model appears to be
a defect in the release of insulin from the
pancreas. For example, insulin-releasing
agents such as glucose and tolbutamide
failed to elevate basal plasma insulin in
the face of demonstrably adequate stores
of pancreatic insulin (Weinkove et al.,
1976). This fact, taken in conjunction with
our data on glucagon-mediated insulin
release in cachectic cancer patients, sug-
gests a similar underlying mechanism for
glucose intolerance in human neoplasia.
From the foregoing discussion and the
data presented above, the glucose intoler-
ance exhibited by both cachectic cancer
patients and protein-deficient weanling
rats, seems to originate from a state of
malnutrition due to reduced dietary in-
take of protein and increased protein
demand. Hence, in order to improve the
nutritional status of advanced cancer
patients it may be necessary not only to
increase their dietary intake but at the
same time to somehow reduce the meta-
bolic activity of tumour tissue. Failure to
achieve these goals simultaneously may
explain why, in the past, protein repletion
alone has been unsuccessful in treating
malignant cachexia, whilst similar treat-
ment of non-malignant cachexia has
resulted in a gain in weight and in total
circulating albumin (Peden et al., 1957).
REFERENCES
ALBANO, J. D., EKINS, R. P., MARITZ, G. & TURNER,
R. C. (1972) A sensitive, precise radioimmunoassay
of serum insulin relying on charcoal separation of
bound and free hormone moieties. Acta Endo-
crinol., 70, 487.
ARIEL, I. M. (1949) The nature of postoperative
hypoproteinemia in patients with gastro-intestinal
cancer. Surg. Gynecol. Ob8tet., 88, 185.
EDWARDS, S. (1919) Blood sugar tolerance in cancer.
J. Indiana State Med. Assoc., 12, 296.
FENNINGER, L. D. & MIDER, G. B. (1954) Energy and
nitrogen metabolism in cancer. Adv. Cancer Res.,
2, 229.
GLICKSMAN, A. S. & RAWSON, R. W. (1956) Diabetes
and altered carbohydrate metabolism in patients
with cancer. Cancer, 9, 1127.
GRODSKY, G. M., BENNETT, L. L., SMITH, D. F. &
SCHMID, F. G. (1967) Effect ofpulse administration
of glucose or glucagon on insulin secretion in vivo.
Metabolism, 16, 222.
HEARD, C. R. C. (1966) Effects of severe protein-
calorie deficiency on the endocrine control of
carbohydrate metabolism. Diabetes, 15, 78.
HOLROYDE, C. P., GABUZDA, T. G., PUTNAM, R. C.,
PAVIE, P. & REICHARD, G. A. (1975) Altered
glucose metabolism in metastatic carcinoma.
Cancer Res., 35, 3710.
MADDEN, S. C. & WHIPPLE, G. H. (1940) Plasma
proteins: their source, production and utilization.
Physiol. Rev., 20, 194.
MARKS, P. A. & BISHOP, J. S. (1956) Alterations in
carbohydrate metabolism associated with neo-
plasia in man. Proc. Am. Ass. Cancer Res., 2, 131.
MARKS, P. A. & BISHOP, J. S. (1957) Glucose meta-
bolism insubjects with neoplastic disease: response
to insulin and glucose tolerance. Follow-up
studies. Proc. Am. Ass. Cancer Res., 2, 228.
MIDER, G. B., TESLUK, H. & MORTON, J. J. (1948)
Effect of Walker carcinoma 256 on food intake,
body-weight, and nitrogen metabolism on growing
rats. Acta Un. Int. Cancer, 6, 409.
MILNER, R. D. G. (1971) Metabolic and hormonal
responses to glucose and glucagon in patients with
infantile malnutrition. Pediatr. Res., 5, 33.
PEDEN, J. C., BOND, L. F. & MAXWELL, M. (1957)
Comparative protein repletion in cancer and non-
cancer cachexia. Am. J. Clin. Nutr., 5, 305.
SHERMAN, C. D. JR., MORTON, J. J. & MIDER, G. B.
(1950) Potential sources of tumour nitrogen.
Cancer Res., 10, 374.
SMITH, S. R., EDGAR. P. J., POZEFSKY, T., CHHETRI,
M. K. & PROUT, T. E. (1975) Insulin secretion and
glucose tolerance in adults with protein-calorie
malnutrition. Metabolism, 24, 1073.
THEOLOGIDES, A. (1972) Pathogenesis of cachexia in
cancer. A review and a hypothesis. Cancer, 29,
484.292 B. JASANI, L. J. DONALDSON, J. G. RATCLIFFE AND G. S. SOKHI
WATERHOUSE, C., FENNINGER, L. D. & KEUTMANN,
E. H. (1951) Nitrogen exchange and calorie
expenditure in patients with malignant neoplasms.
Cancer, 4, 500.
WEINKOVE, C., WEINKOVE, E. A. & PIMSTONE, B. L.
(1976) Glucose tolerance and insulin release in
malnourished rats. Clin. Sci. Mol. Med., 50, 153.
WINZLER, R. J. (1953) Plasma proteins in cancer.
Adv. Cancer Res., 1, 503.